Head-to-head · WeighScore
Direct Meds vs LaSara Medical Group
The verdict
Direct Meds takes it — 82.6/100 to 54.5/100.
Direct Meds grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the few programs offering an oral/sublingual route alongside injectable — semaglutide from ~$179 sublingual (~$297 injectable), tirzepatide ~$224/$399, with an intro promo near $147, all-inclusive and no membership.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Direct Meds | LaSara Medical Group |
|---|---|---|
| WeighScore | 82.6/100 | 54.5/100 |
| Grade | B− | C |
| Scorecard rank | #19 | #455 |
| Semaglutide | $179/mo | $289/mo (compounded) |
| Tirzepatide | $224/mo | $399/mo (bundle, compounded) |
| Coverage | Not publicly listed | Coverage not published |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #19 · B−
Strengths
- Rare oral/sublingual option in addition to injectable
- All-inclusive pricing with no separate membership fee
- Both molecules — semaglutide and tirzepatide
- Intro promotional pricing near $147
Where it loses points
- Compounded only — not FDA-approved
- Pricing is company-stated, not independently live-verified
- Newer and somewhat ambiguous (operates across multiple domains)
- States served are not disclosed
Graded #455 · C
Strengths
- Multi-modality clinic — compounded GLP-1s alongside TRT, peptides, B12, NAD+, sermorelin, and enclomiphene
- National telehealth plus an in-person option in Southern California — uncommon hybrid model
- Free initial consultation
- Active promotional pricing (30% off sitewide at the time of review)
- GLP-1 pricing now published on product pages: compounded semaglutide from $233/mo, tirzepatide from $325/mo on annual bundles
Where it loses points
- Legal entity name and state of incorporation not disclosed
- Compounding pharmacy partner not named
- LegitScript certification status not confirmed
- Per-state availability not listed despite the national-telehealth claim
- Lab work and ongoing monitoring inclusion not clearly disclosed for the multi-modality menu
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.